Neupogen (filgrastim) Global Market Report 2025

Global Neupogen (filgrastim) Market Report 2025

Neupogen (filgrastim) Global Market Report 2025 ) – By Drug Type (Biologic, Biosimilar), By Indication (Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

Name: Neupogen (filgrastim) Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Neupogen (filgrastim) Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Neupogen (filgrastim) Global Market Report 2025

Proud Members Of

Neupogen (filgrastim) Market Definition

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells in the bone marrow. It is used to prevent infection in patients with neutropenia caused by chemotherapy, bone marrow transplantation, or certain medical conditions.

The main drug types of neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are derived from living organisms and involve complex manufacturing processes to produce targeted therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and others. These are distributed by various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Neupogen (filgrastim) Market Segmentation

The neupogen (filgrastim)market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Neupogen (filgrastim) Market Size and growth rate 2025 to 2029: Graph

Neupogen (filgrastim) Market Size 2025 And Growth Rate

The neupogen (filgrastim) market size has grown strongly in recent years. It will grow from $1,330.69 million in 2024 to $1,404.70 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to an increase in cancer prevalence, growth in awareness about chemotherapy-induced neutropenia, improvements in healthcare infrastructure, early approvals for Neupogen biosimilars, and rising global healthcare spending.

Neupogen (filgrastim) Market Growth Forecast

The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1,727.05 million in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising demand for cost-effective neutropenia treatment, expansion of healthcare access in emerging markets, increased government support for biosimilar penetration, improved focus on personalized medicine, and a growing elderly population. Major trends in the forecast period include increasing research and development investments in biosimilars, advancements in drug delivery systems for neutropenia treatments, rising partnerships for oncology drug commercialization, a stronger focus on patient affordability programs, and the development of next-generation G-CSF products.

Book your 30 minutes free consultation with our research experts

Neupogen (filgrastim) Market Driver: Rising Diseases Prevalence Boosts Neupogen Market Growth By Enhancing Immunity

An increase in prevalence of various diseases is expected to propel the growth of the neupogen (filgrastim) market going forward. Diseases are abnormalities in the structure or function of the body that produce specific symptoms or affect specific locations, often caused by infections, genetics, environmental factors, or lifestyle choices. The rising prevalence of various diseases is driven by factors such as aging populations, sedentary lifestyles, increasing pollution levels, poor dietary habits, and the global spread of infectious pathogens. Neupogen (filgrastim) addresses the complications of chemotherapy-induced neutropenia by stimulating the production of neutrophils, thereby enhancing the immune system's ability to combat infections in patients with weakened immunity. It is instrumental in reducing hospitalization rates, managing infection risks, and supporting uninterrupted cancer treatment regimens for patients undergoing intensive therapies. For instance, in April 2024, according to Allergy UK, a UK-based national charity, more than 21 million people in the UK are affected by allergies, which became the most commonly reported chronic health condition in 2022, and projections indicate that by 2026, half of Europe's population will experience at least one allergy. Additionally, in June 2022, according to the data published by the Macmillan Cancer Support, a UK-based cancer charity, the number of people living with cancer reached 3 million in 2022 and is projected to rise to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Therefore, the increase in prevalence of various diseases is driving the growth of the neupogen (filgrastim) market.

Neupogen (filgrastim) Market Driver: Government Led Healthcare Research and Development Initiatives A Boost for Neupogen (filgrastim)

Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the neupogen (filgrastim) market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve certain goals, or create positive changes in society. Several government authorities are initiating various healthcare initiatives to support various aspects including neupogen (filgrastim). For instance, in 2022, according to the Department of Health and Social Care, a UK-based government authority, the UK government announced £260 million (US $270.65) million in funding to boost healthcare research and manufacturing. This was committed by BEIS and DHSC to support NHS-led health research into diagnostics and treatment through new privacy-preserving platforms and clinical research services, and £60 million (US $63.60 million) to help expand life sciences manufacturing in the UK. Therefore, Government initiatives for research and development in healthcare drives the neupogen (filgrastim) market.

Global Neupogen (filgrastim) Market Major Players

Major companies operating in the neupogen (filgrastim) market include Amgen Inc.

Global Neupogen (filgrastim) Market Trend: Innovative Filgrastim Biosimilars Enhance Affordability And Accessibility For Chemotherapy-Induced Neutropenia Treatment

The key trend in the neupogen (filgrastim) market is focusing on developing innovative products as filgrastim biosimilar solutions to provide a cost-effective and accessible alternative for treating chemotherapy-induced neutropenia. Filgrastim biosimilar solutions are biologic medications that closely mimic the original filgrastim (Neupogen) in terms of safety, efficacy, and structure, used primarily to stimulate the production of neutrophils in patients undergoing chemotherapy to prevent neutropenia. For instance, in November 2022, Amneal Pharmaceuticals, a US-based pharmaceutical company, and Kashiv Biosciences, a US-based biopharmaceutical company, launched Releuko (filgrastim-ayow), a biosimilar referencing Neupogen (filgrastim), in the US market. Releuko features intravenous and subcutaneous formulations available in single-dose vials and prefilled syringes, offering dosing flexibility for healthcare providers. Its significance lies in providing a cost-effective treatment option for chemotherapy-induced neutropenia, making critical oncology care more accessible, and addressing the rising demand for biosimilars in the market.

Regional Outlook For The Global Neupogen (filgrastim) Market

North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neupogen (filgrastim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Neupogen (filgrastim) Market?

The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neupogen (filgrastim) Industry?

The neupogen (filgrastim) market research report is one of a series of new reports from The Business Research Company that provides neupogen (filgrastim) market statistics, including neupogen (filgrastim) industry global market size, regional shares, competitors with a neupogen (filgrastim) market share, detailed neupogen (filgrastim) market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. This neupogen (filgrastim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neupogen (filgrastim) Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1,404.70 billion
Revenue Forecast In 2034	CAGR of 5.3% from 2025 to 2034
Growth Rate	2024
Base Year For Estimation	2019-2024
Actual Estimates/Historical Data	2025 - 2029 - 2034
Forecast Period	Revenue in USD Billion and CAGR from 2025 to 2034
Market Representation	1) By Drug Type: Biologic, Biosimilar 2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Segments Covered	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Regional Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Country Scope	Amgen Inc.
Key Companies Profiled	Request for Sample
Customization Scope	Explore Purchase Options
Pricing And Purchase Options

1. Executive Summary

2. Neupogen (filgrastim) Market Characteristics

3. Neupogen (filgrastim) Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route Of Administration (ROA)

3.3. Mechanism Of Action (MOA)

3.4. Safety And Efficacy

4. Neupogen (filgrastim) Market Trends And Strategies

5. Neupogen (filgrastim) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Neupogen (filgrastim) Growth Analysis And Strategic Analysis Framework

6.1. Global Neupogen (filgrastim) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis Of End Use Industries

6.3. Global Neupogen (filgrastim) Market Growth Rate Analysis

6.4. Global Neupogen (filgrastim) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

6.5. Global Neupogen (filgrastim) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

6.6. Global Neupogen (filgrastim) Total Addressable Market (TAM)

7. Global Neupogen (filgrastim) Market Pricing Analysis & Forecasts

8. Neupogen (filgrastim) Market Segmentation

8.1. Global Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Biologic

Biosimilar

8.2. Global Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chemotherapy Induced Neutropenia

Chronic Neutropenia

Others

8.3. Global Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

9. Global Neupogen (filgrastim) Market Epidemiology Of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence And Prevalence of Clinical Indications

10. Neupogen (filgrastim) Market Regional And Country Analysis

10.1. Global Neupogen (filgrastim) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. Global Neupogen (filgrastim) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Neupogen (filgrastim) Market

11.1. Asia-Pacific Neupogen (filgrastim) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Neupogen (filgrastim) Market

12.1. China Neupogen (filgrastim) Market Overview

12.2. China Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

12.3. China Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

12.4. China Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Neupogen (filgrastim) Market

13.1. India Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. India Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. India Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Neupogen (filgrastim) Market

14.1. Japan Neupogen (filgrastim) Market Overview

14.2. Japan Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. Japan Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. Japan Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Neupogen (filgrastim) Market

15.1. Australia Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.2. Australia Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Australia Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Neupogen (filgrastim) Market

16.1. South Korea Neupogen (filgrastim) Market Overview

16.2. South Korea Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. South Korea Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.4. South Korea Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Neupogen (filgrastim) Market

17.1. Western Europe Neupogen (filgrastim) Market Overview

17.2. Western Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Western Europe Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.4. Western Europe Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Neupogen (filgrastim) Market

18.1. UK Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. UK Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. UK Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Neupogen (filgrastim) Market

19.1. Germany Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Germany Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Germany Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Neupogen (filgrastim) Market

20.1. France Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. France Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. France Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neupogen (filgrastim) Market

21.1. Eastern Europe Neupogen (filgrastim) Market Overview

21.2. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Neupogen (filgrastim) Market

22.1. North America Neupogen (filgrastim) Market Overview

22.2. North America Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. North America Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.4. North America Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Neupogen (filgrastim) Market

23.1. USA Neupogen (filgrastim) Market Overview

23.2. USA Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. USA Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. USA Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Neupogen (filgrastim) Market

24.1. Canada Neupogen (filgrastim) Market Overview

24.2. Canada Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. Canada Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. Canada Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Neupogen (filgrastim) Market

25.1. South America Neupogen (filgrastim) Market Overview

25.2. South America Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. South America Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. South America Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Neupogen (filgrastim) Market

26.1. Middle East Neupogen (filgrastim) Market Overview

26.2. Middle East Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. Middle East Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. Middle East Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Neupogen (filgrastim) Market

27.1. Africa Neupogen (filgrastim) Market Overview

27.2. Africa Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Africa Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.4. Africa Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Neupogen (filgrastim) Market Competitive Landscape And Company Profiles

28.1. Neupogen (filgrastim) Market Competitive Landscape

28.2. Neupogen (filgrastim) Market Company Profiles

28.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Neupogen (filgrastim) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Neupogen (filgrastim) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Neupogen (filgrastim) Market

32. Recent Developments In The Neupogen (filgrastim) Market

33. Neupogen (filgrastim) Market High Potential Countries, Segments and Strategies

33.1 Neupogen (filgrastim) Market In 2029 - Countries Offering Most New Opportunities

33.2 Neupogen (filgrastim) Market In 2029 - Segments Offering Most New Opportunities

33.3 Neupogen (filgrastim) Market In 2029 - Growth Strategies

33.3.1 Market Trend Based Strategies

33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations

34.2. Currencies

34.3. Historic And Forecast Inflation Rates

34.4. Research Inquiries

34.5. The Business Research Company

34.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Neupogen (filgrastim) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Neupogen (filgrastim) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Asia-Pacific, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Asia-Pacific, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Asia-Pacific, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: China, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: China, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: China, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: India, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: India, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: India, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: Japan, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: Japan, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Japan, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Australia, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Australia, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Australia, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: South Korea, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: South Korea, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: South Korea, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Western Europe, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Western Europe, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Western Europe, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: UK, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: UK, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: UK, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Germany, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Germany, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Germany, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: France, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: France, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: France, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Eastern Europe, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Eastern Europe, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Eastern Europe, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: North America, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: North America, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: North America, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: USA, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: USA, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: USA, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Canada, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Canada, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Canada, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: South America, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: South America, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: South America, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Middle East, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Middle East, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Middle East, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Africa, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Africa, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Africa, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Amgen Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Neupogen (filgrastim) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Neupogen (filgrastim) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Asia-Pacific, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Asia-Pacific, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Asia-Pacific, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: China, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: China, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: China, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: India, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: India, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: India, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: Japan, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: Japan, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Japan, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Australia, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Australia, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Australia, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: South Korea, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: South Korea, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: South Korea, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Western Europe, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Western Europe, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Western Europe, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: UK, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: UK, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: UK, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Germany, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Germany, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Germany, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: France, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: France, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: France, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Eastern Europe, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Eastern Europe, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Eastern Europe, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: North America, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: North America, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: North America, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: USA, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: USA, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: USA, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Canada, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Canada, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Canada, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: South America, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: South America, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: South America, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Middle East, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Middle East, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Middle East, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Africa, Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Africa, Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Africa, Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Amgen Inc. Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the cell and gene therapy market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the pharmaceutical drugs and biologics logistics market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the acne drugs market research report 2022 with industry size, share, segments and market growth

Filgrastim Biosimilars Global Market Report 2025 – By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing organization), By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pegfilgrastim Biosimilars Global Market Report 2025 – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Uncomplicated Urinary Tract Infection Treatment Global Market Report 2025 – By Drug Class (Gepotidacin, Probenecid, Sulfonamide, Tetracycline, Nitrofuran), By Source Of Infection (Hospital-Acquired Urinary Tract Infection (UTI), Community-Acquired Urinary Tract Infection (UTI)), By Gender (Male, Female), By Distribution Channel (Hospital Pharmacies, Gynecology And Urology Clinics, Retail Pharmacies, Online Drug Stores) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Chlamydia Infection Diagnostics And Therapeutics Global Market Report 2025 – By Type (Nucleic Acid Amplification Tests (NAATS), Direct Fluorescent Tests, Macrolides, Quinolones, Sulfonamides, Tetracycline, Aminopenicillins), By Type Of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection), By Application (Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Chlamydia Infection Diagnostics Global Market Report 2025 – By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test, Other Test Types), By Type Of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection), By Application (Hospitals, Specialty Clinics, Diagnostic Centers), By End User (Diagnostics, Therapeutics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Chlamydia Infection Treatment Global Market Report 2025 – By Treatment (Chlamydia Culture, Urine Culture, Enzyme Immunoassays, Nucleic Acid Amplification Test), By Causative Organisms (Chlamydia Trachomatis, Chlamydophila Pneumoniae, Other Causative Organisms), By Route Of Administration (Oral, Injectables, Other Routes Of Administration), By End-Users (Hospitals, Homecare, Specialty Clinics , Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Candida Infection Testing Global Market Report 2025 – By Type (Invasive Candidiasis, Candidemia), By Test Type (Vaginal pH Test, Nucleic Acid Amplification Testing (NAAT), Microbiome Test), By Application (Hospital, Laboratory) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Infection Prevention Global Market Report 2025 – By Product (Sterilization Equipment, Disinfectors, Consumables), By Infection Type (Microbial Infections, Healthcare Associated Infections), By End User (Hospitals And Clinics, Pharmaceutical Companies, Clinical Laboratories, Medical Device Companies, Life Science Industry, Academic And Research Center) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Neupogen (filgrastim) market?

How will the Neupogen (filgrastim) market drivers and restraints affect the market dynamics? What forces will shape the Neupogen (filgrastim) industry going forward?

The Neupogen (filgrastim) market major growth driver - Rising Diseases Prevalence Boosts Neupogen Market Growth By Enhancing Immunity. For further insights on the Neupogen (filgrastim) market, request a sample here

What is the forecast market size or the forecast market value of the Neupogen (filgrastim) market?

The Neupogen (filgrastim) market size has grown strongly in recent years. The neupogen (filgrastim) market size has grown strongly in recent years. It will grow from $1,330.69 million in 2024 to $1,404.70 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to an increase in cancer prevalence, growth in awareness about chemotherapy-induced neutropenia, improvements in healthcare infrastructure, early approvals for Neupogen biosimilars, and rising global healthcare spending. The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1,727.05 million in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising demand for cost-effective neutropenia treatment, expansion of healthcare access in emerging markets, increased government support for biosimilar penetration, improved focus on personalized medicine, and a growing elderly population. Major trends in the forecast period include increasing research and development investments in biosimilars, advancements in drug delivery systems for neutropenia treatments, rising partnerships for oncology drug commercialization, a stronger focus on patient affordability programs, and the development of next-generation G-CSF products. For further insights on the Neupogen (filgrastim) market, request a sample here

How is the Neupogen (filgrastim) market segmented?

The neupogen (filgrastim)market covered in this report is segmented –
1) By Drug Type: Biologic; Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies For further insights on the Neupogen (filgrastim) market, request a sample here

Which region has the largest share of the Neupogen (filgrastim) market? What are the other regions covered in the report?

Who are the major players in the Neupogen (filgrastim) market?

Major companies operating in the neupogen (filgrastim) market include Amgen Inc. . For further insights on the Neupogen (filgrastim) market, request a sample here.

What are the key trends in the Neupogen (filgrastim) market?

Major trends in the Neupogen (filgrastim) market include Innovative Filgrastim Biosimilars Enhance Affordability And Accessibility For Chemotherapy-Induced Neutropenia Treatment. For further insights on the Neupogen (filgrastim) market, request a sample here.

What are the major opportunities in the Neupogen (filgrastim) market? What are the strategies for the Neupogen (filgrastim) market?

For detailed insights on the major opportunities and strategies in the Neupogen (filgrastim) market, request a sample here.

How does the Neupogen (filgrastim) market relate to the overall economy and other similar markets?

For detailed insights on Neupogen (filgrastim)'s relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Neupogen (filgrastim) industry?

For detailed insights on the mergers and acquisitions in the Neupogen (filgrastim) industry, request a sample here.

What are the key dynamics influencing the Neupogen (filgrastim) market growth? SWOT analysis of the Neupogen (filgrastim) market.

For detailed insights on the key dynamics influencing the Neupogen (filgrastim) market growth and SWOT analysis of the Neupogen (filgrastim) industry, request a sample here.